TARGETED INHIBITION OF LEUKEMIA INHIBITORY FACTOR (LIF)/LIFR AXIS FOR THE TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER
$960,000FY2018Department of the ArmyDOD
Evestra, Inc., Schertz TX
Investigators
View source on USAspending →TARGETED INHIBITION OF LEUKEMIA INHIBITORY FACTOR (LIF)/LIFR AXIS FOR THE TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER · GrantIndex